德国儿童青少年1型糖尿病1期和2期进展可能性评分分层疾病进展率
Fr1da研究对211,464名1.75-10岁儿童筛查胰岛自身抗体,485名早期1型糖尿病患儿按ADA标准分期并随访3-6个月。进展可能性评分(PLS)将1期患儿2年进展至3期风险从43.7%分层至0%,非OGTT评分可识别低(1.7%)和中(24.6%)风险。
要点
- PLS可分层1期和2期1型糖尿病患儿2年进展至3期风险。
- 高PLS者2年风险43.7%,中/低PLS者分别为4.7%和0%。
- 非OGTT评分可识别低(1.7%)和中(24.6%)2年风险个体。
核心结论
- PLS和新型非OGTT评分可分层短期至中期进展至3期的风险,应考虑用于指导监测实践和临床试验资格。
研究设计与样本
- Fr1da研究对211,464名1.75-10岁儿童进行胰岛自身抗体筛查,485名早期1型糖尿病患儿参与分期,随访3-6个月。
主要发现
- 485名参与分期儿童中360名(74.2%)诊断为1期,其中105名进展至3期(中位随访3.3年)。
- PLS将1期患儿2年进展至3期风险从高PLS的43.7%(95%CI 24.3-58.1)分层至中PLS的4.7%(1.7-7.7)和低PLS的0%。
- 在仅有单一血糖异常的2期患儿中,PLS可将2年进展至3期风险从42.4%(95%CI 22.8-57.0)分层至5.6%(0.0-15.6)。
- 基于IA-2A滴度类别、HbA1c、肥胖和IA-2近膜表位自身抗体阳性的非OGTT评分可识别低(1.7%)和中(24.6%)2年风险个体。
关键数值与推荐
- PLS为HbA1c、90分钟OGTT血糖和IA-2A滴度的复合评分。
- 非OGTT评分基于IA-2A滴度类别、HbA1c、肥胖和IA-2近膜表位自身抗体阳性。
- 早期分期使用ADA标准通过OGTT和HbA1c分类为1期或2期。
临床怎么用
- PLS和非OGTT评分可用于指导1型糖尿病早期患儿的监测频率和临床试验入组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To stratify the progression rate to clinical stage 3 type 1 diabetes in children with early-stage disease. RESEARCH DESIGN AND METHODS: The Fr1da study tested 211,464 children aged 1.75-10 years for islet autoantibodies. Children with early-stage type 1 diabetes were classified as stage 1 or stage 2 by oral glucose tolerance test (OGTT) and hemoglobin A1c (HbA1c) using current American Diabetes Association criteria and were followed 3-6 months. We applied our previously developed progression likelihood score (PLS), a composite of HbA1c, 90-min OGTT glucose, and islet antigen 2 antibodies (IA-2A) titer, and developed a non-OGTT-based score using multivariable Cox proportional hazards models to stratify progression rates to stage 3. RESULTS: Of 485 children who participated in staging, 360 (74.2%) were diagnosed with stage 1. Of these, stage 3 developed in 105 (median follow-up 3.3 years). PLS stratified the 2-year risk for stage 3 from 43.7% (95% CI 24.3-58.1) in children with high PLS to 4.7% (1.7-7.7) and 0% in those with intermediate or low PLS. Adding the variable obesity improved the existing model. In children with stage 2 with a single dysglycemic abnormality, PLS could stratify 2-year risk for stage 3 from 42.4% (95% CI 22.8-57.0) to 5.6% (0.0-15.6). A non-OGTT-based score based on IA-2A titer categories, HbA1c, obesity, and autoantibody positivity for IA-2 juxtamembrane epitopes could identify individuals with low (1.7%) and moderate (24.6%) 2-year risk. CONCLUSIONS: The PLS and a novel non-OGTT-based score can stratify the short- to medium-term progression rates to stage 3 and should be considered for guiding monitoring practices and clinical trial eligibility.
引用
- Weiss A, Chakievska L, Achenbach P, et al. Stratifying the Rate of Disease Progression by Progression Likelihood Scores in Children and Adolescents With Stage 1 and Stage 2 Type 1 Diabetes in Germany. Diabetes Care. 2026. PMID: 41401417. doi:10.2337/dc25-2184
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。